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Monoclonal antibodys were identiﬁed by selection in the presence of monoclonal antibodies with
neutralizing activity. The VP1 amino acid alterations in these mutants were: (1) K73→E (in loop BC); (2)
D77→E (in loop BC); (3) K171→R (in loop EF); and (4) Q175→H (in loop EF). These residues are clustered in
close proximity to each other on the surface of the native capsid protein, strongly suggesting that they form a
conformational epitope directly recognized by the neutralizing antibody. To our knowledge, the present
study represents the ﬁrst experimental mapping of a neutralization epitope of a polyomavirus family
member. Structural information regarding the neutralization epitope should be useful for clarifying the
extent of cross-reactivity exhibited by the humoral immune response towards related primate poly-
omaviruses (e.g., SV40, BKV, and JCV).
Published by Elsevier Inc.Introduction
Members of the polyomavirus family are non-enveloped viruses
with double-stranded circular DNA genomes of approximately 5 kb.
Some of these viruses are recognized as oncogenic agents because of
their capacity to induce tumors in experimental animals. Two
polyomaviruses, JCV and BKV, are highly prevalent in the human
population and can be pathogenic in immunocompromised hosts
(Hirsch and Steiger, 2003; Seth et al., 2003). Recently, two distinct
polyomavirus isolates (KI and WU) were recovered from human
respiratory secretions (Allander et al., 2007; Gaynor et al., 2007). In
addition, the genome of a third novel human polyomavirus was
identiﬁed inMerkel cell carcinomas (Feng et al., 2008). The prevalence
and pathogenicity of these newly discovered human viruses have yet
to be fully investigated.
SV40 is a polyomavirus whose natural host is the rhesus macaque;
it is closely related to BKV and JCV, as the genomes of these viruses
share greater than 70% nucleotide identity. SV40 was initially isolated
as an adventitious agent that contaminated early poliovirus vaccines
produced using primary rhesus kidney cells (Sweet and Hilleman,
1960). Most of the contaminated vaccine lots in North America were
administered between 1955 and 1963 (Poulin and DeCaprio, 2006;
Stratton et al., 2003). However, a recent study has provided evidence
of contamination by a major eastern European manufacturer that may
have persisted until approximately 1978 (Cutrone et al., 2005). The
controversy surrounding the possibility that SV40 is circulating in the
human population at a low level, perhaps as a consequence ofCBER, FDA, 29 Lincoln Drive,
.
nc.contaminated polio vaccines, has been a subject of intense investiga-
tion and remains unresolved (Stratton et al., 2003).
The extensive homology shared by BKV, JCV, and SV40 presents a
technical challengewhen conducting seroepidemiological studies that
assess exposure to each virus (Shah et al., 2004). Interpretation of
results from assays that measure serum antibody binding to
immobilized polyomavirus capsid antigen (e.g., ELISA) is complicated
by antibody cross-reactivity; in most cases, SV40 reactivity can be
eliminated by pre-incubation of the “positive” sera with BKV or JCV
antigens (Carter et al., 2003; Viscidi et al., 2003). Thus, it may be
difﬁcult to reach unequivocal conclusions about the prevalence of
SV40-reactive antibodies in human sera based on such methods.
Assays capable of detecting functional antibodies that neutralize
infectivity are likely to achieve higher speciﬁcity than ELISA. The
development of serological assays based on the detection of neutraliz-
ing antibodies should be facilitated by understanding the structural
elements of the polyomavirus capsid targeted by such antibodies.
The surface of the polyomavirus icosahedral capsid consists of 360
copies of the major structural protein VP1 organized as 72 homo-
pentameric units (Liddington et al., 1991; Stehle et al., 1996). The
minor structural proteins, VP2 and VP3, are sequestered within the
outer shell formed by VP1 (Chen et al., 1998). Thus, VP1 is the only
structural element of the intact virion directly accessible to the
humoral immune system.
VP1 neutralization epitopes have not been experimentally char-
acterized for any member of the polyomavirus family. Isolates of BKV
have been organized into at least four serogroups that can be
discriminated by hemagglutination-inhibition and neutralization
assays (Knowles et al., 1989). However, experimental identiﬁcation
of the BKV capsid residues that contribute to the neutralization
epitope(s) has not been reported.
Table 1











CC-NE1 CC10 1724 A→G 73 K→E BC loop
EE-NE2 EE10 1738 T→A 77 D→E BC loop
EE-NE3 EE10 2019 A→G 171 K→R EF loop
2032 A→T 175 Q→H EF loop
EE-NE3A N/A 2019 A→G 171 K→R EF loop
EE-NE3B N/A 2032 A→T 175 Q→H EF loop
a Nucleotide number according to SV40 776 sequence (AF316139).
117H. Murata et al. / Virology 381 (2008) 116–122Monoclonal antibodies with neutralizing activity towards SV40
have been reported (Babé et al., 1989). These antibodies do not react
with denatured VP1 protein (in SDS-PAGE Western blot analysis),
suggesting that they target one or more conformational epitopes.
The determinants of a conformational epitope may be non-
contiguous along a polypeptide sequence and occur in spatial
proximity only when the protein is properly folded. Thus, an
epitope-mapping strategy using small peptides most likely would
be unsuccessful.
We chose to identify the neutralization epitope(s) of SV40 by
determining the amino acid residues altered in mutants that escaped
neutralization bymonoclonal antibodies. The structural context of the
residues identiﬁed in this manner strongly suggests that they are




We chose to identify residues contained in the neutralization
epitope(s) of SV40 VP1 using a genetic selection for escape mutants.
This approach has been successfully applied to study a number of
RNA viruses. The error-prone nature of the polymerase that
replicates the genome of an RNA virus results in genetic hetero-
geneity (quasi-species) in a given virus population from which
desired mutants can be selected. For a DNA virus such as SV40,
genetic heterogeneity must be artiﬁcially introduced. The strategy is
outlined in the diagram shown in Fig. 1A. Brieﬂy, a library consisting
of SV40 VP1 mutants was generated by random mutagenesis.Fig. 1. (A) Strategy for the isolation of SV40 VP1 escape mutants selected in the presence
of neutralizing monoclonal antibodies. (B) The region of VP1 targeted for PCR-based
random mutagenesis. The positions of the PCR primers are indicated by the solid
arrows; the targeted region (∼0.9 kb) can be excised by digestionwith AccI and BamHI.Mutants of interest were recovered from this library following
virus infection in the presence of monoclonal antibodies with
neutralizing activity towards SV40. Mutations associated with
neutralization resistance were identiﬁed by sequencing the VP1
genes from the escape mutants, and their activity was conﬁrmed by
transferring them to wild-type SV40.
Construction and characterization of the VP1 mutant library
The VP1 gene was targeted for PCR-based random mutagenesis
using a commercially available kit. The boundaries for the mutagen-
ized region (SV40 776 nucleotide numbers 1629 to 2592), as deﬁned
by the PCR primers, spanned nearly the entire VP1 coding region but
excluded the 5 prime region of the VP1 gene that overlaps the coding
region for VP2/3 (Fig. 1B). The plasmid selected for mutagenesis,
pSV776.1, consisted of the SV40 776 genome cloned into the Asp718
site of the pUC19-based vector pHM1; the unique Asp718 site in the
SV40 776 genome occurs outside of the coding region of VP1. The
procedure resulted in a bacterial library consisting of 23,000 clones.
Twenty random bacterial clones were subjected to sequence analysis;
14 out of the 20 clones (70%) harbored mutations in the VP1 region (1
to 5 nucleotide changes per clone). The observed mutation frequency
was consistent with the expected frequency provided by the
mutagenesis kit manufacturer. If an idealized library were to contain
independent recombinants harboring all possible single-nucleotide
changes, such a library would have a complexity of approximately
4000 (4 possible nucleotide bases for every position in the ∼1 kb
target region). Using this calculation as a frame of reference, the
achieved complexity of our library (70% of 23,000=∼16,000) was
considered to be adequate.
The plasmid library was linearized with Asp718 and converted into
infectious viruses through transfection of 293TwtT cells. A choice was
made to use human cells rather than permissive simian cells so that
the representation of the library would not be substantially biased by
multiple cycles of virus replication. The parental 293 cell line and its
derivatives can be transfected with high efﬁciency. In addition,
293TwtT cells have been engineered to express the wild-type SV40
large T antigen. Both of these features were thought to facilitate the
attainment of higher virus titers in a single round of production. The
library virus was harvested by subjecting the cells to three freeze/thaw
cycles at 72 h post-transfection.
Selection of neutralization escape mutants
Neutralization escape mutants were selected by inoculating CV-1
cells with the virus library in the presence of SV40-speciﬁc neutraliz-
ing monoclonal antibodies CC10 and EE10 (Babé et al., 1989). Out of
four inoculated ﬂasks (two ﬂasks placed under selection with each
monoclonal antibody with 104 pfu of neutralized virus library per
ﬂask), three developed cytopathic effects (CPE) characteristic of SV40
within 3 weeks. Control ﬂasks similarly inoculated with unmutagen-
ized SV40 776 neutralized with either CC10 or EE10 showed no CPE,
demonstrating that the amounts of monoclonal antibodies used were
sufﬁcient to neutralize wild-type SV40.
Table 2
Neutralization phenotype of SV40 VP1 mutants
Monoclonal
antibody












CC10 512 b1 512 1 64 512
EE10 512 b1 b1 b1 b1 64
Fig. 2. Plaque morphology of the SV40 VP1 neutralization escape mutants. CV-1 cells were inoculated with the indicated viruses. Plaques were visualized 14 days post-infection.
Plaque titer values are in parentheses (pfu/mL).
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inoculate fresh cultures of CV-1 cells in the presence of the original
selection antibody, and viral genomic DNA was isolated. The VP1
regions from the recovered DNAwere released by digestion with both
AccI and BamHI (producing a 0.9 kb fragment) and used to replace the
corresponding segment of pSV776.1 (Figs. 1A and B). This step ensured
that the genetic basis for the phenotypes associated with viruses
generated using the infectious clones can be assigned unequivocally to
the VP1 coding region. The VP1 gene segments (AccI/BamHI) were
subjected to DNA sequencing. Six independent clones derived from
each selection ﬂask were sequenced. The sequence analysis demon-
strated that each of these ﬂasks yielded an independent mutant, since
the sequences of the 6 clones obtained from each ﬂask were identical
to each other (i.e., one mutant species was predominant in the
population of each ﬂask). The sequencing data suggest that the
mutants of interest are to be found in the library at a frequency of
approximately one per 104 pfu.
The three recovered neutralization escape (NE) mutants were
designated as CC-NE1, EE-NE2, and EE-NE3 (Table 1). Mutant CC-NE1,
selected by antibody CC10, contained a single-nucleotide change
(1724 A→G) that replaced lysine 73 of VP1with glutamate; this amino
acid residue is located in the surface BC loop. Mutant EE-NE2, selected
by antibody EE10, contained a single-nucleotide change (1738 T→A)
that replaced aspartate 77 with glutamate; this residue also occurs in
the BC loop. Mutant EE-NE3, selected by antibody EE10, contained two
nucleotide changes (2019 A→G and 2032 A→T) that resulted in the
replacement of lysine 171 and glutamine 175 with arginine and
histidine, respectively; both of these residues reside in the surface EF
loop. To evaluate the phenotypic effect of the individual mutations
found in EE-NE3, two additional mutants were generated by site-
directed mutagenesis: EE-NE3A (K171→R) and EE-NE3B (Q175→H)
(Table 1).
Plaque morphology of neutralization escape mutants
Virus stocks of mutants CC-NE1, EE-NE2, EE-NE3, EE-NE3A, and EE-
NE3B were generated by transfecting the Asp718-digested full-lengthclones into CV-1 cells. These stocks were titered on CV-1 cells; the
plaques were stained on day 14 post-infection (Fig. 2). Mutants EE-
NE2, EE-NE3, EE-NE3A, and EE-NE3B produced plaques with dia-
meters comparable with those produced by 776 (3–6 mm), while
mutant CC-NE1 produced small plaques (b3 mm). The plaque titers of
all virus stocks exceeded 107 pfu/mL, suggesting that themutations do
not cause gross defects in replication efﬁciency.
Neutralization escape phenotype
The neutralization escape phenotype was veriﬁed by a 96-well
plate infectivity assay according to the method described by Minor et
al. (2003). The neutralization titers of antibodies CC10 and EE10 are
shown in Table 2 as the reciprocal of the last dilution in the series that
inhibited infectivity. The neutralization titer was 512 towards wild-
type virus (SV40 776) for both CC10 and EE10; this value was in
agreement with data obtained by plaque-neutralization assays (data
not shown). Mutant EE-NE2 appeared to be resistant to EE10 (the
antibody used for selection; titer ofb1), but remained susceptible to
CC10 to the same extent as 776 (titer of 512). Mutants CC-NE1 and EE-
NE3 were resistant to neutralization by both CC10 and EE10
(neutralization titers for each antibody of 1 or less). EE-NE3 is the
double mutant harboring both K171→R and Q175→H. Mutant EE-
NE3A, harboring the single K171→R change, was highly resistant to
EE10 (titer of b1), but modestly resistant to CC10 (titer of 64). Mutant
EE-NE3B, harboring the single Q175→H change, was modestly
119H. Murata et al. / Virology 381 (2008) 116–122resistant to EE10 (titer of 64); it remained fully susceptible to CC10
(titer of 512). These results conﬁrm that the antibody selection scheme
was successful in identifying relevant mutants.
Discussion
Starting from a collection of random SV40 VP1 mutants, we have
isolated escape mutants resistant to the neutralizing activity of SV40-
speciﬁc monoclonal antibodies. The fact that these VP1 escape
mutants were viable, yielding titers similar to wild-type SV40,
demonstrated that the structures of the mutant capsids were not
grossly altered. Due to the availability of the crystallographic structure
of the SV40 capsid (Liddington et al., 1991; Stehle et al., 1996), the
locations of the residues mutated in CC-NE1, EE-NE2, and EE-NE3
could be mapped in the natively folded capsid protein (Fig. 3). The
residue in yellow is lysine 73 (BC loop; mutated to glutamate in CC-
NE1). The residue in green is aspartate 77 (BC loop; mutated to
glutamate in EE-NE2). The residues in red and purple are lysine 171
and glutamine 175, respectively (EF loop; both mutated in EE-NE3).
These residues are closely clustered in three dimensions, particularly
K73, D77, and K171, despite the fact that these residues are non-
contiguous. K73 and D77 occur in the same loop (BC) with three
intervening residues between them; a sharp turn in this loop brings
K73 and D77 in close apposition. K171 and Q175 also occur in the same
loop (EF) separated by three residues; however, Q175 in the context of
the folded protein is somewhat separated from the tight cluster
formed by K73, D77, and K171. This is consistent with the observation
that the primary contribution to the neutralization escape phenotype
of the double mutant EE-NE3 is made by K171→R rather than by
Q175→H (Table 2; see the phenotype of the single mutants EE-NE3A
and EE-NE3B).
Collectively, the data strongly suggest that K73, D77, and K171 are
constituents of a neutralization epitope because they: (i) confer
resistance to neutralization by monoclonal antibodies; (ii) occur in
viable mutants; (iii) occur in VP1 surface loops; and (iv) cluster in
three dimensions. The observation that at least two VP1 surface loops
(BC and EF) contribute to this epitope is consistent with the ﬁnding ofFig. 3. The location of the residues mutated in the SV40 VP1 neutralization escape mutants. T
and D77, respectively (both in the BC loop). The red and purple residues indicate K171 and
software (National Center for Biotechnology Information; Bethesda, MD) based on structuraBabé et al. that the monoclonal antibodies CC10 and EE10 recognize a
conformational epitope dependent on correct protein folding (Babé et
al., 1989). Mutants CC-NE1 and EE-NE3 are resistant to neutralization
by both CC10 and EE10, suggesting that the structural targets
recognized by these two antibodies overlap. While Q175 might also
be directly involved in antibody recognition, it is possible that the
modest effect on neutralization resistance conferred by Q175→H
alone is due to an indirect mechanism that subtly perturbs the
structure of the capsid rather than a direct mechanism resulting from
a change in the epitope. The cooperativity exhibited by Q175→H and
K171→R to confer resistance to CC10 might support this latter notion
(Table 2; compare the phenotypes of EE-NE3, EE-NE3A, and EE-NE3B).
SV40 VP1 shares N80% amino acid sequence identity with VP1 of
human polyomaviruses JCV and BKV. Despite the extensive degree of
homology, these viruses display distinctive properties (e.g., receptor
usage and serological identity) that are presumably governed by the
VP1 capsid protein. Fig. 4 shows the alignment of the VP1 protein
sequences of SV40 and BKV (Dunlop isolate). Many of the divergent
residues occur in the surface loops. The residues altered in the SV40
neutralization escapemutants are marked by asterisks. On the basis of
sequence analysis, Jin et al. have postulated that the region spanning
residues 61 to 83 of BKV VP1 (loop BC) contains a determinant
responsible for serotypic differences among BKV isolates (Jin et al.,
1993). It is notable that two of the mutations identiﬁed in the present
study (K73→E and D77→E) map to the corresponding region of SV40
VP1.
To our knowledge, the present study is the ﬁrst to map a
neutralization epitope of a member of the polyomavirus family. It
may be possible to generalize the experimental approach developed
for SV40 in order to undertake a comparable analysis of human
polyomaviruses such as BKV and JCV. Mapping of the neutralization
epitope(s) of polyomavirus VP1 would be highly desirable because
neutralizing antibodies presumably target functional domains on the
capsid surface. Further characterization of neutralization escape
mutants might reveal critical VP1 structure/function relationships
such as the residues involved in interaction with the cellular receptor
(the ganglioside GM1 can serve as a cellular receptor for SV40; Tsai etwo views of the SV40 pentamer are shown. The yellow and green residues indicate K73
Q175, respectively (both in the EF loop). The images were generated using the Cn3D
l data deposited by Stehle et al. (1996).
Fig. 4. Alignment of the VP1 proteins of SV40 and BKV (Dunlop isolate). The divergent residues are highlighted in red. The major external surface loops are underlined (according to
Liddington et al., 1991). The residues mutated in the SV40 VP1 neutralization escape mutants are indicated by asterisks.
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epitope might also be exploited for practical applications. For
example, detailed epitope mapping might facilitate the development
of serological assays with enhanced speciﬁcity that could be useful for
epidemiological evaluation of humanpolyomavirus infection. Further-
more, structural data might aid the design of prophylactic and
therapeutic vaccines against diseases caused by polyomaviruses
(e.g., BKV nephropathy in transplant patients). Finally, SV40 is
currently being developed by a number of investigators as a vector
for gene therapy and recombinant vaccines (Kimchi-Sarfaty and
Gottesman, 2004; Strayer et al., 2005). Knowledge of the epitope
structure can provide useful information about how the immune
system might react in recipients of SV40-based therapies. An analogy
is provided by recombinant adenovirus vectors, which are presently
used in a variety of experimental contexts. The utility of a particular
adenovirus vector as a vaccine or gene therapy vector (e.g., Ad5-based
vectors) appears to be limited by the prevalence of prior exposure to
that adenovirus type in the target population (Sumida et al., 2005); in
some cases, host neutralizing antibodies can be evaded by genetically
engineering the neutralization epitope of the recombinant vector
(Roberts et al., 2006). Structural information regarding the neutraliza-
tion epitope might be useful in overcoming similar issues should they
arise for SV40-based vectors.
Materials and methods
Cells lines
CV-1 cells were obtained from the American Type Culture
Collection (ATCC; Manassas, VA). 293TwtT cells, derived from 293T
cells (ATCC), have been stably transfected with an expression
construct encoding wild-type SV40 large T antigen (the parental
293T cells express the temperature-sensitive large T antigen mutant
tsA1609). Details of the generation of 293TwtT will be described in a
separate publication (Sheng et al.; manuscript in preparation). CV-1
and 293TwtT cells were grown in DMEM supplemented with 10% fetal
bovine serum (FBS; HyClone; Logan, Utah) and 4 mM glutamine. The
hybridomas CC10 and EE10, expressing monoclonal antibodies with
neutralizing activity towards SV40, were kindly provided by W. A.
Scott (University of Miami School of Medicine; Miami, FL). Thehybridomas were grown in DMEM supplemented with 10% FBS, 4 mM
glutamine, and 1×hypoxanthine/aminopterin/thymidine (diluted
from a 500X stock; ATCC).
Construction of the SV40 VP1 random mutagenesis library
The starting plasmid was pSV776.1, which contained a copy of the
SV40 776 genome cloned into pHM1 (Murata et al., 2008) using the
unique Asp718 site. The VP1 coding regionwas targeted for PCR-based
random mutagenesis using the GeneMorphII EZClone Domain
Mutagenesis Kit (Stratagene; La Jolla, CA) according to the manufac-
turer's protocol. The PCR primers ﬂanking the mutagenized region
were: GTTCTAGGAGTTAAAACTGGAGTAGAC (sense with respect to
VP1; nucleotide numbers 1607–1633) and TCACTGCATTCTAGTTGTGG-
TTTGTCC (anti-sense with respect to VP1; nucleotide numbers 2593–
2567). PCR conditions were: 95 °C for 2 min; 95 °C for 30 s, 50 °C for
30 s, and 72 °C for 1.5 min (30 cycles); 72 °C for 10 min. The PCR
product was puriﬁed by electrophoresis on a 1% agarose gel and
extracted using the Qiagen QIAquick kit (Qiagen; Valencia, CA). The
mutagenized ampliﬁcation product was used as “megaprimers” to
anneal to and extend the remaining length of pSV776.1. The
thermocycler conditions were: 95 °C for 1 min; 95 °C for 50 s, 60 °C
for 50 s, and 68 °C for 16 min (25 cycles). The reaction products were
digested with DpnI to eliminate the unmutagenized parental plasmid.
Following concentration by ethanol precipitation, the digested DNA
was transformed into XL10-Gold competent cells (Stratagene). The
resulting primary library consisted of 23,000 bacterial transformants.
The bacterial colonies were scraped from the plates into a small
volume of liquid bacterial broth, and, following the addition of an
equal volume of sterile 50% glycerol, stored frozen at −80 °C.
Conversion of the plasmid VP1 random mutagenesis library into
infectious virions
Plasmid derived from the VP1 random mutagenesis library was
puriﬁed using the GenElute HP kit (Sigma; St. Louis, MO). The SV40
genome was excised from the library plasmid by digestion with
Asp718. The digested DNA was subjected to ethanol precipitation and
resuspended in sterile H2O. Four micrograms of digested DNA were
transfected into 50% conﬂuent 293TwtT cells grown in 60 mm dishes
121H. Murata et al. / Virology 381 (2008) 116–122using 16 μL of the Mirus TransIT 293 reagent (Mirus Bio; Madison, WI)
according to the manufacturer's protocol. Twenty-four hours later, the
transfection medium was replaced with 3 mL of fresh medium per
dish. Viruses generated in the transfected cells were harvested at 72 h
by 3 cycles of freeze/thaw. The resulting library virus stock (titer:
2×104 pfu/mL) was clariﬁed by low-speed spin (200 RCF for 5 min)
and stored frozen at −20 °C until use.
Selection of SV40 neutralization escape mutants
For each independent selection,104 pfu of the library virus in 0.5mL
were neutralized with 0.5 mL of undiluted hybridoma culture super-
natant; 1 mL of the mixture was used to inoculate a T25 ﬂask of
conﬂuent CV-1 cells. Flasks inoculated in this manner weremonitored
daily for SV40 CPE.When the CPEwas 4+, theﬂaskswere subjected to 3
freeze/thaw cycles. The contents of the ﬂasks were transferred to
sterile tubes. Following clariﬁcation by low-speed centrifugation (200
RCF for 5min), the supernatants were stored frozen at −20 °C until use.
Recovery of mutant genomic DNA encoding VP1
The viruses recovered from a selection ﬂask (0.5 mL) were used to
inoculate freshly conﬂuent CV-1 cells grown in a T75 ﬂask; the culture
medium contained the appropriate monoclonal antibody hybridoma
supernatant used for selection at a ﬁnal dilution of 1:100. When the
CPE was approximately 2+, SV40 genomic DNAwas isolated according
themethod of Hirt (1967) asmodiﬁed by Peden et al. (1980). The 0.9 kb
fragment encoding most of VP1 was excised by digesting the Hirt DNA
with AccI and BamHI; this fragment was used to replace the
corresponding fragment of the parental plasmid pSV776.1. The cloned
AccI/BamHI fragment was sequenced using the Big Dye Terminator
version 3.1 DNA sequencing reagent (Applied Biosystems; Foster City,
CA) with the following two ﬂanking primers: GAACTGCTCCTCAGTG-
GATGTTGCC (sense; nucleotide numbers 1426–1451) and GTTAA-
CTTGTTTATTGCAGCTTATAATGG (anti-sense; nucleotide numbers
2671–2643).
Site-directed mutagenesis
Site-directed mutagenesis of pSV776.1 to introduce 171 K→R
(mutant EE-NE3A) and 175 Q→H (mutant EE-NE3B) was performed
using the QuikChange XL Kit (Stratagene). The mutagenized plasmids
were sequenced in the relevant region to verify the nucleotide
alteration.
Generation of infectious SV40 VP1 mutants by transfection of cloned
SV40 DNA
Two micrograms of cloned SV40 VP1 mutant DNA (derivative of
pSV776.1) were digested with Asp718. The digested DNA was
subjected to ethanol precipitation and resuspended in 150 μL of
sterile TE buffer (pH 8.0). The excised SV40 genome was transfected
into CV-1 cells grown in a T25 ﬂask (∼80% conﬂuent) using 15 μL of the
PolyFect transfection reagent (Qiagen) according to the manufac-
turer's protocol. The monolayer was typically lysed within 10 days.
The lysate was frozen and thawed three times, subjected to low-speed
centrifugation (200 RCF for 5 min) to remove debris, and stored frozen
at −20 °C until use.
Plaque assay
Plaque assays were performed using CV-1 cells grown in 60 mm
dishes as described previously (Murata et al., 2008). Plaques were
assessed on day 14 post-infection. To enhance the contrast, the overlay
was stripped, and the cells were ﬁxed withmethanol and stained with
crystal violet (0.04% in H2O).Neutralization assay
Neutralization of SV40 was assessed using a 96-well plate
infectivity assay (Minor et al., 2003). Twenty-ﬁve microliters of SV40
(∼100 pfu) were neutralized with 25 μL of antibody dilution (in an 8-
fold dilution series of hybridoma supernatant) in a microtiter cell
culture plate well; a suspension of cells (200 μL; 5×104 cells) was then
added to the well. Following incubation at 37 °C for 10 days, the
culture was assessed microscopically for SV40 CPE.
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